PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.103
https://www.valueinhealthjournal.com/article/S1098-3015(18)33403-X/fulltext
Title :
PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33403-X&doi=10.1016/j.jval.2018.09.103
First page :
Section Title :
Open access? :
No
Section Order :
458